220 related articles for article (PubMed ID: 23350355)
1. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne EJ; Klostergaard J; Mandal PK; Liao WS; Lu Z; Gao F; Bast RC; Robertson FM; McMurray JS
J Exp Ther Oncol; 2012; 10(2):155-62. PubMed ID: 23350355
[TBL] [Abstract][Full Text] [Related]
2. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain.
McMurray JS; Mandal PK; Liao WS; Klostergaard J; Robertson FM
JAKSTAT; 2012 Oct; 1(4):263-347. PubMed ID: 24058783
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
Mandal PK; Gao F; Lu Z; Ren Z; Ramesh R; Birtwistle JS; Kaluarachchi KK; Chen X; Bast RC; Liao WS; McMurray JS
J Med Chem; 2011 May; 54(10):3549-63. PubMed ID: 21486047
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3.
Mandal PK; Liao WS; McMurray JS
Org Lett; 2009 Aug; 11(15):3394-7. PubMed ID: 19594124
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity.
Mandal PK; Morlacchi P; Knight JM; Link TM; Lee GR; Nurieva R; Singh D; Dhanik A; Kavraki L; Corry DB; Ladbury JE; McMurray JS
J Med Chem; 2015 Nov; 58(22):8970-84. PubMed ID: 26506089
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).
Mandal PK; Ren Z; Chen X; Kaluarachchi K; Liao WS; McMurray JS
Int J Pept Res Ther; 2013 Mar; 19(1):3-12. PubMed ID: 24707243
[TBL] [Abstract][Full Text] [Related]
7. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
9. Targeting SH2 domains in breast cancer.
Morlacchi P; Robertson FM; Klostergaard J; McMurray JS
Future Med Chem; 2014; 6(17):1909-26. PubMed ID: 25495984
[TBL] [Abstract][Full Text] [Related]
10. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.
Shin DS; Kim HN; Shin KD; Yoon YJ; Kim SJ; Han DC; Kwon BM
Cancer Res; 2009 Jan; 69(1):193-202. PubMed ID: 19118003
[TBL] [Abstract][Full Text] [Related]
12. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
13. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
14. Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity.
Jeon YJ; Jung SN; Yun J; Lee CW; Choi J; Lee YJ; Han DC; Kwon BM
Cancer Sci; 2015 Apr; 106(4):413-20. PubMed ID: 25611086
[TBL] [Abstract][Full Text] [Related]
15. Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
Wang J; Zhang L; Chen G; Zhang J; Li Z; Lu W; Liu M; Pang X
Breast Cancer Res Treat; 2014 Nov; 148(2):279-89. PubMed ID: 25301089
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the binding of high affinity phosphopeptides to Stat3.
McMurray JS
Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
[TBL] [Abstract][Full Text] [Related]
18. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
19. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
Page BD; Fletcher S; Yue P; Li Z; Zhang X; Sharmeen S; Datti A; Wrana JL; Trudel S; Schimmer AD; Turkson J; Gunning PT
Bioorg Med Chem Lett; 2011 Sep; 21(18):5605-9. PubMed ID: 21788134
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells.
Rhee YH; Jeong SJ; Lee HJ; Lee HJ; Koh W; Jung JH; Kim SH; Sung-Hoon K
BMC Cancer; 2012 Jan; 12():28. PubMed ID: 22260501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
